^
Association details:
Evidence:
Evidence Level:
Sensitive: D – Preclinical
Source:
Title:

ZW191, a novel FRa-targeting antibody drug conjugate bearing a topoisomerase 1 inhibitor payload

Published date:
04/04/2023
Excerpt:
The anti-tumor activity of ZW191 was evaluated in a panel of cell line-derived xenograft (CDX) and patient-derived xenograft (PDX) ovarian cancer models spanning a range of FRa expression...ZW191 demonstrates potent activity in FRa expressing 3D tumor spheroid cultures and effective bystander activity. In a panel of CDX and PDX models representing a range of FRa expression, ZW191 demonstrates compelling anti-tumor activity at exposures that are estimated to be readily achievable in the clinic.
DOI:
10.1158/1538-7445.AM2023-2641